iBio
IBIO
13 hedge funds and large institutions have $267K invested in iBio in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
45% more capital invested
Capital invested by funds: $184K → $267K (+$83K)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$23K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$14.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13K |
| 4 |
VF
Virtu Financial
New York
|
+$5.64K |
| 5 |
BlackRock
New York
|
+$434 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.34K |
IBIO Hedge Fund Activity: Q1 2019 in Review
13 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q1 2019, worth a combined $267K — up 45% from $184K a quarter earlier.
Fund positioning in IBIO was balanced in Q1 2019: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $23K. The largest seller was UBS Group, cutting an estimated $4.34K.
- 13 institutional investors held iBio (IBIO) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $267K of iBio stock for Q1 2019, up 45% quarter-over-quarter.
- 1 fund opened new iBio positions in Q1 2019 and 1 closed out, a net change of 0 holders.
- The largest iBio buyer in Q1 2019 was Citadel Advisors, an estimated $23K added.
- The largest iBio seller in Q1 2019 was UBS Group, an estimated $4.34K sold.
Based on aggregated 13F filings for Q1 2019.